OBJECTIVE: Lipocalin 2 (LCN-2) is an innate immune protein that is expressed by a variety of cells and is highly up-regulated during several pathologic conditions, including immune complex (IC)-mediated inflammatory/autoimmune disorders. However, the function of LCN-2 during IC-mediated inflammation is largely unknown. Therefore, this study was undertaken to investigate the role of LCN-2 in IC-mediated diseases. METHODS: The up-regulation of LCN-2 was determined by enzyme-linked immunosorbent assay in 3 different mouse models of IC-mediated autoimmune disease: systemic lupus erythematosus, collagen-induced arthritis, and serum-transfer arthritis. The in vivo role of LCN-2 during IC-mediated inflammation was investigated using LCN-2-knockout mice and their wild-type littermates. RESULTS: LCN-2 levels were significantly elevated in all 3 of the autoimmune disease models. Further, in an acute skin inflammation model, LCN-2-knockout mice exhibited a 50% reduction in inflammation, with histopathologic analysis revealing notably reduced immune cell infiltration as compared to wild-type mice. Administration of recombinant LCN-2 to LCN-2-knockout mice restored inflammation to levels observed in wild-type mice. Neutralization of LCN-2 using a monoclonal antibody significantly reduced inflammation in wild-type mice. In contrast, LCN-2-knockout mice developed more severe serum-induced arthritis compared to wild-type mice. Histologic analysis revealed extensive tissue and bone destruction, with significantly reduced neutrophil infiltration but considerably more macrophage migration, in LCN-2-knockout mice compared to wild-type mice. CONCLUSION: These results demonstrate that LCN-2 may regulate immune cell recruitment to the site of inflammation, a process essential for the controlled initiation, perpetuation, and resolution of inflammatory processes. Thus, LCN-2 may present a promising target in the treatment of IC-mediated inflammatory/autoimmune diseases.
OBJECTIVE:Lipocalin 2 (LCN-2) is an innate immune protein that is expressed by a variety of cells and is highly up-regulated during several pathologic conditions, including immune complex (IC)-mediated inflammatory/autoimmune disorders. However, the function of LCN-2 during IC-mediated inflammation is largely unknown. Therefore, this study was undertaken to investigate the role of LCN-2 in IC-mediated diseases. METHODS: The up-regulation of LCN-2 was determined by enzyme-linked immunosorbent assay in 3 different mouse models of IC-mediated autoimmune disease: systemic lupus erythematosus, collagen-induced arthritis, and serum-transfer arthritis. The in vivo role of LCN-2 during IC-mediated inflammation was investigated using LCN-2-knockout mice and their wild-type littermates. RESULTS:LCN-2 levels were significantly elevated in all 3 of the autoimmune disease models. Further, in an acute skin inflammation model, LCN-2-knockout mice exhibited a 50% reduction in inflammation, with histopathologic analysis revealing notably reduced immune cell infiltration as compared to wild-type mice. Administration of recombinant LCN-2 to LCN-2-knockout mice restored inflammation to levels observed in wild-type mice. Neutralization of LCN-2 using a monoclonal antibody significantly reduced inflammation in wild-type mice. In contrast, LCN-2-knockout mice developed more severe serum-induced arthritis compared to wild-type mice. Histologic analysis revealed extensive tissue and bone destruction, with significantly reduced neutrophil infiltration but considerably more macrophage migration, in LCN-2-knockout mice compared to wild-type mice. CONCLUSION: These results demonstrate that LCN-2 may regulate immune cell recruitment to the site of inflammation, a process essential for the controlled initiation, perpetuation, and resolution of inflammatory processes. Thus, LCN-2 may present a promising target in the treatment of IC-mediated inflammatory/autoimmune diseases.
Authors: Guanhu Bao; Matthew Clifton; Trisha M Hoette; Kiyoshi Mori; Shi-Xian Deng; Andong Qiu; Melanie Viltard; David Williams; Neal Paragas; Thomas Leete; Ritwij Kulkarni; Xiangpo Li; Belinda Lee; Avtandil Kalandadze; Adam J Ratner; Juan Carlos Pizarro; Kai M Schmidt-Ott; Donald W Landry; Kenneth N Raymond; Roland K Strong; Jonathan Barasch Journal: Nat Chem Biol Date: 2010-06-27 Impact factor: 15.040
Authors: Hong Wu; Eric Santoni-Rugiu; Elisabeth Ralfkiaer; Bo T Porse; Claus Moser; Niels Høiby; Niels Borregaard; Jack B Cowland Journal: Respir Res Date: 2010-07-15
Authors: Manfred Nairz; Igor Theurl; Andrea Schroll; Milan Theurl; Gernot Fritsche; Ewald Lindner; Markus Seifert; Marie-Laure V Crouch; Klaus Hantke; Shizuo Akira; Ferric C Fang; Günter Weiss Journal: Blood Date: 2009-08-21 Impact factor: 22.113
Authors: Sobeyda B Gomez-Chou; Agnieszka Katarzyna Swidnicka-Siergiejko; Niharika Badi; Myrriah Chavez-Tomar; Gregory B Lesinski; Tanios Bekaii-Saab; Matthew R Farren; Thomas A Mace; Carl Schmidt; Yan Liu; Defeng Deng; Rosa F Hwang; Liran Zhou; Todd Moore; Deyali Chatterjee; Huamin Wang; Xiaohong Leng; Ralph B Arlinghaus; Craig D Logsdon; Zobeida Cruz-Monserrate Journal: Cancer Res Date: 2017-03-01 Impact factor: 12.701
Authors: Rebeca Martín; Florian Chain; Sylvie Miquel; Jane M Natividad; Harry Sokol; Elena F Verdu; Philippe Langella; Luis G Bermúdez-Humarán Journal: Hum Vaccin Immunother Date: 2014-04-14 Impact factor: 3.452
Authors: Rebeca Martín; Sylvie Miquel; Florian Chain; Jane M Natividad; Jennifer Jury; Jun Lu; Harry Sokol; Vassilia Theodorou; Premysl Bercik; Elena F Verdu; Philippe Langella; Luis G Bermúdez-Humarán Journal: BMC Microbiol Date: 2015-03-21 Impact factor: 3.605